

## UNITED STATES DEPARTMENT OF COMMERCE **United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

GOET ZEIRST NAMED INVENTOR ATTORNEY DOCKET NO. APPLICATION NO. FILING DATE

HM12/0530

FLEHR HOHBACH TEST ALBRITTON & HERBERT FOUR EMBARCADERO CENTER SUITE 3400 SAN FRANCISCO CA 94111-4187

| HARRI | EXAMINER |  |
|-------|----------|--|

ART UNIT PAPER NUMBER

05/30**/8**1

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

Application No. **09/274,752** 

Applicant(s)

Goetzl And An

Examiner

Alana M. Harris, Ph. D.

Art Unit 1642



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE \_\_\_\_\_ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) X This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quay/835 C.D. 11; 453 O.G. 213. Disposition of Claims 4) X Claim(s) 1-32 is/are pending in the applica 4a) Of the above, claim(s) \_\_\_\_\_\_ is/are withdrawn from considera 5) Claim(s) is/are allowed. 6) Claim(s) · \_\_\_\_ is/are objected to. 7) ☐ Claim(s) \_ are subject to restriction and/or election requirem 8) 🗶 Claims <u>1-32</u> **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner. is: a∭ approved b)☐disapproved. 11) The proposed drawing correction filed on 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) ☐ All b) ☐ Some\* c) ☐None of: 1. 

Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \*See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 20) X Other: Restriction Election Facsimile Transmission 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

Application/Control Number: 09274752

Art Unit:

## **DETAILED ACTION**

## Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-11, drawn to an isolated nucleic acid, classified in class 536, subclass 23.1.
  - II. Claims 12-16, drawn to a protein, classified in class 530, subclass 350.
  - III. Claim 17, drawn to a monoclonal antibody, classified in class 530, subclass 387.1.
  - IV. Claims 18-20, drawn to a method for screening a bioactive agent, classified in class435, subclass 4.
- 2. The inventions are distinct, each from the other because of the following reasons:

Groups I-III are structurally and functionally different products which are made by different methods and have different uses. The examination of all groups would require different searches in the U.S. Patent Shoes and the scientific literature and would require the consideration of different patentability issues.

Invention of Groups II-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP)

Application/Control Number: 09274752

Page 3

Art Unit:

§ 806:05(h)). In the instant case the products of Group II and III can be used in the method of Groups IV.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Attempts to reach Todd A. Lorenz by telephone on May 23, 2001 to request an oral election to the above restriction requirement were unsuccessful.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Art Unit:

- 7. Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Anthony Caputa, Ph.D., Supervisory Patent Examiner at Anthony.Caputa@uspto.gov or 703-308-3995. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.
- 8. Papers related to this application may be submitted to Group 1642 by facsimile transmission. Papers should be faxed to Group 1642 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Crystal Mall One Fax Center telephone number is (703) 308-4242 or (703) 305-3014.
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris whose telephone number is (703)306-5880. The examiner can normally be reached on Monday through Friday from 6:30 am to 4:00 pm, with alternate Fridays off. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703)308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703)308-0196.

Mella ) Moll SHEELA HUFF PRIMARY EXAMINER